Computational systems biology approaches to anti-angiogenic cancer therapeutics

Stacey D Finley; Liang-Hui Chu; Aleksander S Popel

doi:10.1016/j.drudis.2014.09.026

Computational systems biology approaches to anti-angiogenic cancer therapeutics

Drug Discov Today. 2015 Feb;20(2):187-97. doi: 10.1016/j.drudis.2014.09.026. Epub 2014 Oct 5.

Authors

Stacey D Finley¹, Liang-Hui Chu², Aleksander S Popel²

Affiliations

¹ Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: sfinley@usc.edu.
² Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Abstract

Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. Anti-angiogenic therapy involves inhibiting multiple cell types, molecular targets, and intracellular signaling pathways. Computational tools are useful in guiding treatment strategies, predicting the response to treatment, and identifying new targets of interest. Here, we describe progress that has been made in applying mathematical modeling and bioinformatics approaches to study anti-angiogenic therapeutics in cancer.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors* / pharmacology
Angiogenesis Inhibitors* / therapeutic use
Drug Discovery*
Humans
Models, Biological*
Neoplasms / drug therapy
Systems Biology

Substances

Angiogenesis Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding